This study is testing if adding a new drug called durvalumab, an immunotherapy, to the normal chemotherapy can help treat certain types of breast cancer. Immunotherapy is a type of treatment that helps your immune system fight cancer. The normal chemotherapy drugs used here are paclitaxel, doxorubicin, and cyclophosphamide, which work by killing cancer cells or stopping them from growing. The study is for patients with a specific type of breast cancer called MammaPrint High 2 Risk (MP2) stage II-III, which means the cancer is more likely to respond to these treatments.

• ⏱ The study lasts until death or up to 10 years of follow-up.
• 💉 Participants will undergo chemotherapy with or without durvalumab.
• 💵 You may get reimbursed for participating but check with the study team for details.

Participants must be at least 18 years old, have specific types of breast cancer, and have not had previous treatments for this cancer. You'll have regular visits for treatment and check-ups. It's important to consider possible side effects and discuss with your doctor if this study is right for you.